ADMA BIOLOGICS, INC. (ADMA)
Score window: May. 30, 2025 to May. 29, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Sep. 29, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of ADMA Biologics, Inc.'s Form 10-K for the fiscal year ended December 31, 2024. The correspondence emphasizes that the responsibility for the acc… | Read Filing EDGAR |
| Sep. 26, 2025 | CORRESP | Concern from SEC | Moderate | ADMA Biologics, Inc. submitted a supplemental letter to the SEC in response to comments regarding their Form 10-K for the fiscal year ended December 31, 2024. The SEC expressed co… | Read Filing EDGAR |
| Sep. 16, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed ADMA Biologics, Inc.'s response to a previous comment letter regarding their Form 10-K for the fiscal year ended December 31, 2024. They express appreciation … | Read Filing EDGAR |
| Aug. 13, 2025 | CORRESP | Concern from SEC | Moderate | ADMA Biologics, Inc. submitted a supplemental letter to the SEC in response to comments regarding their Form 10-K for the fiscal year ended December 31, 2024. The SEC raised conce… | Read Filing EDGAR |
| Jul. 30, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed ADMA Biologics, Inc.'s response to a previous comment letter regarding their Form 10-K for the fiscal year ended December 31, 2024. They are requesting furthe… | Read Filing EDGAR |
| Jul. 23, 2025 | CORRESP | Neutral/Informational | Moderate | ADMA Biologics, Inc. submitted a response to the SEC regarding comments on their Form 10-K for the fiscal year ended December 31, 2024. The SEC requested a detailed breakout of re… | Read Filing EDGAR |
| Jul. 16, 2025 | UPLOAD | Concern from SEC | High | The SEC has conducted a limited review of ADMA Biologics, Inc.'s Form 10-K for the fiscal year ended December 31, 2024, focusing on the financial statements and related disclosure… | Read Filing EDGAR |